Zoetis Inc.
corporate_fare Company Profile
Zoetis Inc. (NYSE:ZTS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 14 items for ZTS at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-08-13, rated 7/10. Across its 14 most recent items scored 7 or higher, the top rating is 8/10, with 8 rated 8 or above. Recent SEC coverage for ZTS spans 10-Q, 8-K, DEF 14A, 10-K.
Recent high-impact activity:
- FDA Grants Emergency Use Authorization for Zoetis' Simparica Trio Against New World Screwworm
- Zoetis Q2 2026: Flat Revenue as U.S. Companion Animal Weakness Meets Restructuring and Legal Headwinds
- Zoetis Slashes 2026 Guidance by 10%, U.S. Pet Sales Plunge 11%
- Zoetis Issues 2026 Adj EPS Guidance of $6.15-$6.25
- Zoetis Slashes 2026 Guidance as Companion Animal Demand Weakens; Q2 Revenue Flat
Financial Snapshot
Short Interest & Short Volume
3.83 days to coverFINRA reported short interest of 17,390,071 shares in ZTS as of the September 15, 2026 settlement, a 10.5% decrease from the prior period — about 3.8 days to cover at its recent average daily volume. On October 2, 2026, 50.8% of ZTS volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.